Matthew D. Morin

TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS

Ying Wang, Lijing Su, Matthew D. Morin et al. · Proceedings of the National Academy of Sciences · 2016 · 169 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice

Ying Wang, Lijing Su, Matthew D. Morin et al. · Proceedings of the National Academy of Sciences · 2018 · 111 citations · Full text

Life Sciences, Immunology, Oncology +17

Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim

Lijing Su, Ying Wang, Junmei Wang et al. · Journal of Medicinal Chemistry · 2019 · 86 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists

Matthew D. Morin, Ying Wang, Brian T. Jones et al. · Journal of the American Chemical Society · 2018 · 60 citations

Life Sciences, Immunology, Medicinal Chemistry +13

Total Synthesis of Lepadiformine Alkaloids using <i>N</i>-Boc α-Amino Nitriles as Trianion Synthons

Matthew A. Perry, Matthew D. Morin, B. W. Slafer et al. · The Journal of Organic Chemistry · 2012 · 43 citations

Pharmacy, Chemistry, Medicinal Chemistry +13